TITLE

Incident Hepatitis C Virus in Women with Human Immunodeficiency Virus Infection

AUTHOR(S)
Augenbraum, M.; Goedert, J. J.; Thomas, D.; Feldman, J.; Seaberg, E. C.; French, A. L.; Robison, E.; Nowicki, M.; Terrault, N.
PUB. DATE
November 2003
SOURCE
Clinical Infectious Diseases;11/15/2003, Vol. 37 Issue 10, p1357
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Individuals infected with human immunodeficiency virus type 1 (HIV­1) are frequently coinfected with hepatitis C virus (HCV). Acute HCV infection is often asymptomatic and poorly understood. We conducted a historical prospective study of HCV antibody and viremia in plasma samples obtained during 1994—1999 from a cohort of initially HIV­1­infected, HCV-uninfected women and from HIV­1­HCV­uninfected women. Twenty-two (1.5%) of 1517 experienced seroconversion. Of these, 14 (64%) truly acquired a new infection as assessed by enzyme immunoassay response and new-onset viremia. The incidence rate in HIV­1­infected women was 2.7 cases per 1000 person-years; it was 3.3 cases per 1000 person-years in HIV­1­seronegative women (relative risk, 1.21; P = .75). Acquisition of HCV was associated with any history of drug use (P<.01). Five of 12 viremic, seroconverting individuals cleared viremia. Incident HCV infection among HIV­1­infected and HIV­1­uninfected women was low. It was linked to drug use and commonly resolved.
ACCESSION #
11471083

 

Related Articles

  • Co-infection of Hepatitis C Among HIV-infected Population with Different Risk Groups in Kathmandu, Nepal. Ojha, Chet Raj; Khagendra, K. C.; Shakya, Geeta // Biomedical Research (0970-938X);2013, Vol. 24 Issue 4, p441 

    Prevalence of HCV infection has increased in recent decades as a consequence of its incorporation into effective transmission networks, such as blood transfusion and most notably injecting drug users (IDU). Seroprevalence of Co- infection is common due to the common mode of transmissions in both...

  • Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIV-Infected Patients in Spain, 1997-2006. Cachafeiro, Santiago Pérez; Del Amo, Julia; Iribarren, Jose A.; Lleti, Miguel Salavert; lix^Gutiérrez, Fé; Moreno, Ana; Labarga, Pablo; Pineda, Juan A.; Vidal, Francesc; Berenguer, Juan; Moreno, Santiago // Clinical Infectious Diseases;5/15/2009, Vol. 48 Issue 10, p1467 

    The prevalence of injection drug use decreased from 67.3% in 1997 to 14.5% in 2006 among Spanish patients infected with human immunodeficiency virus (HIV). A parallel decrease in the prevalence of coinfection with hepatitis C virus was observed, from 73.8% in 1997 to 19.8% in 2006. This steady...

  • The Impact of Chronic Hepatitis C Virus Infection on Mortality. Nelson, Kenrad E. // Journal of Infectious Diseases;8/15/2012, Vol. 206 Issue 4, p461 

    The author discusses several researches conducted to investigate the impact of chronic hepatitis C virus (HCV) infection on mortality. He mentions that in a research monitoring 568 patients who acquired non-A, non-B hepatitis without infection identified between 1967 and 1980, researchers found...

  • Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease. Casado, José L.; Del Palacio, María; Moya, Javier; Rodriguez, José M.; Moreno, Ana; Perez-Elías, María J.; Belso, Ana; Dronda, Fernando; Moreno, Santiago // HIV Clinical Trials (Thomas Land Publishers Incorporated);Sep/Oct2011, Vol. 12 Issue 5, p235 

    Purpose: There are few data about the safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with very advanced liver disease.Method: Prospective study of 60 HIV/HCV coinfected patients who underwent a liver biopsy and received a lopinavir-based regimen. The rate of...

  • High rate of seronegative HCV infection in HIV-positive patients. JUNIASTUTI; TAKAKO UTSUMI; NASRONUDIN; ALIMSARDJONO, LINDAWATI; AMIN, MOCHAMAD; ADIANTI, MYRNA; YOSHIHIKO YANO; SOETJIPTO; YOSHITAKE HAYASHI; HAK HOTTA; LUSIDA, MARIA INGE // Biomedical Reports;2014, Vol. 2 Issue 1, p79 

    Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is a significant global health problem. The two viruses are transmitted with high efficacy via blood-to-blood contact, mainly intravenous drug use (IVDU), whereas HCV is less easily transmitted sexually. Antibody...

  • Kronik Hepatit B'li Olgularda Anti Hepatit Delta Virüs (Anti HDV), Anti Hepatit C virüs (Anti-HCV) Antikorları Sıklığının AraÅŸtırılması. İnci, Ayşe; Fincancı, Muzaffer; Müderrisoğlu, Cüneyt // Istanbul Medical Journal;2013, Vol. 14 Issue 2, p109 

    Objective: The aim of this study was to determine the prevalence of Hepatitis Delta Virus (HDV) and Hepatitis C Virus (HCV) in patients chronically infected with Hepatitis B Virus (HBV). Methods: The study was conducted on chronic hepatitis B patients followed in the Istanbul Training and...

  • Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. Pérez-Rodríguez, Ma Teresa; Sopeña, Bernardo; Crespo, Manuel; Rivera, Alberto; del Blanco, Teresa González; Ocampo, Antonio; Martínez-Vázquez, César; Alvaro, Montiel-Jarquín // World Journal of Gastroenterology;3/14/2009, Vol. 15 Issue 10, p1237 

    AIM: To determine the prevalence and clinical relevance of isolated antibodies to hepatitis B core antigen as the only marker of infection ("anti-HBc alone") among human immunodeficiency virus (HIV) type-1 infected patients. Occult hepatitis B infection frequency was also evaluated. METHODS:...

  • Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Jabłonowska, E; Kuydowicz, J // International Journal of STD & AIDS;Sep2014, Vol. 25 Issue 10, p745 

    The aim of this study was to estimate the prevalence of total antibodies to hepatitis A virus (anti-HAV-T) in the group of HIV-positive adults in Lodz region of Poland, and to evaluate the response and long-term immunity after vaccination against hepatitis A virus. In the group of 234...

  • Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Patel, Eshan U.; Cox, Andrea L.; Mehta, Shruti H.; Boon, Denali; Mullis, Caroline E.; Astemborski, Jacquie; Osburn, William O.; Quinn, Jeffrey; Redd, Andrew D.; Kirk, Gregory D.; Thomas, David L.; Quinn, Thomas C.; Laeyendecker, Oliver // Journal of Infectious Diseases;8/1/2016, Vol. 214 Issue 3, p344 

    Background: Sensitive methods are needed to estimate the population-level incidence of hepatitis C virus (HCV) infection.Methods: We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifying the Ortho 3.0 HCV enzyme-linked immunoassay and tested 997...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics